Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSThis is the second blog in the five blog series: Creating a framework for a successful launch. IQVIA analyzed launches globally to identify common launch challenges and pitfalls. Four launch archetypes were identified, "science sells", "market shaping", "who benefits" and "emphasize the difference", each had very specific critical success factors.
For the "science sells" archetype, where there is a high unmet need in the market and high product differentiation the critical success factors are:
Additional challenges for emerging biopharma include:
In this blog we examine the example of:
Incivek (telaprevir) is a protease inhibitor and was approved in the U.S. and Europe for the treatment of hepatitis C infection in 2011.
The window of opportunity for success in a drug launch is very short. The launch trajectory is set in the first 12 to 16 weeks after the launch, and only around a fifth of brands can change their trajectory once the drug hits the market. This means that there is a huge benefit in preparing the market before the launch.
Large pharmaceutical organizations have many resources to call upon in the pre-launch period, This includes more capital, more people, more experience, and more opportunities to start preparation early, sometimes up to five years before launch. In comparison, an emerging biopharma company may only be able to begin preparation around two years before a launch. Therefore, emerging biopharma have to choose how to use their resources more carefully.
Not only was Vertex facing a new market with an all-new commercial team, it was up against a top-ten biopharma company with a product in the same class that was launched within 10 days of Incivek.
However, Vertex had two benefits. Firstly, the hepatitis C area was one of major unmet medical need at the time of the Incivek launch, providing a market with many opportunities. In 2011, there were around 3 million people infected with hepatitis C in the U.S., with around 78% of them unaware of the infection. And secondly, Vertex created a key differentiator – its disease awareness campaign.
The pre-launch disease awareness campaign targeted both physicians and patients. For patients, its aim was to provide scientific information and health education with a patient voice. The campaign featured patient stories and videos, a hepatitis C screener and practical advice, through an unbranded site. Vertex also initiated partnerships with HCV advocacy groups more than a year before approval.
For physicians, Vertex created an unbranded site as well, to jumpstart non-product scientific dialogue and provide access to the latest thinking from thought leaders. The site was designed to make it easy for HCPs to share information with their colleagues.
The campaign meant that Vertex could become recognized for offering products and solutions to the hepatitis C community, from the perspectives of both healthcare professionals and patients, even before Incivek was on the market.
By making the most of its market need and key differentiator, Vertex managed to capture around a 75% share of the market, especially for those with an urgent need for treatment.
While Incivek’s disease awareness campaign was a key product differentiator that enabled the company a unique position in the HCV market, it is important to remember that this was only one element of a much larger launch strategy. Other critical success factors were also important in the launch of Incivek.
To get more insight into the “science sells” archetype visit: A framework for successful biopharma launches for the recorded webinar, supported by a slide presentation.